Cost-effectiveness acceptability curve of PSAs. Across WTPs of $150 000, $104 000, and $50 000 per QALY, emicizumab favored over standard care in 100%, 66%, and 0% of 10 000 Monte Carlo iterations, respectively. In the low-dose emicizumab scenario, emicizumab is favored in 100% of iterations across all accepted WTPs in the United States.